Staff Profile
Dr Catherine Park
Research Associate
- Email: [email protected]
- Address: Life Science Centre Times Square, Newcastle upon Tyne
NE1 4EP
I am a Research Associate within NUTCRI at the International Centre for Life. My area of expertise is the immunological response to myocardial infarction.
Academic background
Masters in Medical Sciences from University of Leeds (2013-2014). Carried out research in the lab or Dr. Thomas Hughes studying the effects of stroma on chemotherapy resistance in breast cancer.
PhD in Biomedical Sciences and Newcastle University (2014-2018) under the supervision of Dr. Niall Kenneth. Research focussed on the effects of hypoxia and reoxygenation on NF-kappaB signalling, and the resulting downstream effects of this signalling on cell proliferation, survival and transcription.
Worked in the lab of Professor James Allan as a research assistant on several projects concerning the treatment of adult onset acute leukemias.
Google scholar: Click here.
- Park CV, Ivanova IG, Kenneth NS. XIAP upregulates expression of HIF target genes by targeting HIF1α for Lys63-linked polyubiquitination. Nucleic Acids Research 2017, 45(16), 9336-9347.
- Ivanova IG, Park CV, Yemm AI, Kenneth NS. PERK/eIF2α signaling inhibits HIF-induced gene expression during the unfolded protein response via YB1-dependent regulation of HIF1α translation. Nucleic Acids Research 2018, 46(8), 3878-3890.
- Tual-Chalot S, García-Collado M, Redgrave RE, Singh E, Davison B, Park C, Lin H, Luli S, Jin Y, Wang Y, Lawrie A, Jakobsson L, Arthur HM. Loss of endothelial Endoglin promotes high-output heart failure through peripheral arteriovenous shunting driven by VEGF signalling. Circulation Research 2020, 126(2), 243-257.
- Ivanova IG, Park CV, Kenneth NS. Translating the Hypoxic Response—the Role of HIF Protein Translation in the Cellular Response to Low Oxygen. Cells 2019, 8(2), 114.
- Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018, 2(10), 1157-1169.